JNJ

234.47

+0.27%↑

UNH

276.38

-2.48%↓

TMO

565.82

-0.55%↓

ABT

108.1

-0.74%↓

ISRG

477.8

-0.19%↓

JNJ

234.47

+0.27%↑

UNH

276.38

-2.48%↓

TMO

565.82

-0.55%↓

ABT

108.1

-0.74%↓

ISRG

477.8

-0.19%↓

JNJ

234.47

+0.27%↑

UNH

276.38

-2.48%↓

TMO

565.82

-0.55%↓

ABT

108.1

-0.74%↓

ISRG

477.8

-0.19%↓

JNJ

234.47

+0.27%↑

UNH

276.38

-2.48%↓

TMO

565.82

-0.55%↓

ABT

108.1

-0.74%↓

ISRG

477.8

-0.19%↓

JNJ

234.47

+0.27%↑

UNH

276.38

-2.48%↓

TMO

565.82

-0.55%↓

ABT

108.1

-0.74%↓

ISRG

477.8

-0.19%↓

Kodu・Aktsiate loetelu・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Avatud

SektorTervishoid

24.97 0.6

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

24.79

Max

25.33

Põhinäitajad
By Trading Economics
Sissetulek	675K 53M
Müük	1.8M 148M
P/E Sektori keskmine	14.62 84.243
Kasumimarginaal	35.57
Töötajad	181
EBITDA	1.7M 80M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+36% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	25. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	449M 3.1B
Eelmine avamishind	24.37
Eelmine sulgemishind	24.97

Uudiste sentiment

By Acuity

100%

337 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

N/A / 24.28 Toetus ja vastupanu

Catalyst Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. veebr 2026, 23:11 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3. veebr 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. veebr 2026, 23:50 UTC

Market Talk

Nikkei May Decline After Hitting All-Time High -- Market Talk

3. veebr 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

3. veebr 2026, 23:41 UTC

Omandamised, ülevõtmised, äriostud

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3. veebr 2026, 23:38 UTC

Tulu

AMD Sales Climb on Help From Data-Center Business -- Update

3. veebr 2026, 23:29 UTC

Omandamised, ülevõtmised, äriostud

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3. veebr 2026, 23:27 UTC

Omandamised, ülevõtmised, äriostud

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3. veebr 2026, 23:25 UTC

Omandamised, ülevõtmised, äriostud

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3. veebr 2026, 23:23 UTC

Omandamised, ülevõtmised, äriostud

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3. veebr 2026, 23:22 UTC

Omandamised, ülevõtmised, äriostud

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3. veebr 2026, 23:19 UTC

Market Talk

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3. veebr 2026, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

3. veebr 2026, 22:56 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3. veebr 2026, 22:40 UTC

Tulu

Amdocs Extends Collaboration With T-Mobile

3. veebr 2026, 22:39 UTC

Tulu

Amdocs 1Q Adj EPS $1.81

3. veebr 2026, 22:39 UTC

Tulu

Amdocs 1Q Rev $1.16B

3. veebr 2026, 22:39 UTC

Tulu

Amdocs 1Q EPS $1.45 >

3. veebr 2026, 22:38 UTC

Tulu

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3. veebr 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3. veebr 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3. veebr 2026, 22:14 UTC

Tulu

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3. veebr 2026, 22:13 UTC

Tulu

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3. veebr 2026, 22:12 UTC

Tulu

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3. veebr 2026, 22:10 UTC

Tulu

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3. veebr 2026, 22:10 UTC

Tulu

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3. veebr 2026, 22:10 UTC

Market Talk

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3. veebr 2026, 22:10 UTC

Tulu

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3. veebr 2026, 22:09 UTC

Tulu

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3. veebr 2026, 22:09 UTC

Tulu

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Võrdlus sarnastega

Hinnamuutus

Catalyst Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

36% tõus

12 kuu keskmine prognoos

Keskmine 34 USD 36%

Kõrge 35 USD

Madal 33 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Catalyst Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Catalyst Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 24.28Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

337 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.